Next, we compared the magnitudes of BCMA and vaccine-specific IgA responses in ALS specimens of individuals primed with two doses of ETVAX with or without 10 μg dmLT (n = 47) (16), followed by a single booster dose of ETVAX 13–23 months later (n = 35, Supplementary Figure 1B) (17). This evidence concerns the gene CD79A and amyotrophic lateral sclerosis.